Literature DB >> 27275486

The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Panagiota Economopoulou1, Christos Perisanidis1, Evaggelos I Giotakis1, Amanda Psyrri1.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) carries a poor prognosis, with low survival rates for advanced stage tumors and minimal improvement in survival trends through the past decades. It is becoming increasingly clear that HNSCC oncogenesis and evolution is characterized by profound immune defects, as cancer cells evade immunosurveillance due to accumulation of genetic mutations and tumor heterogeneity. Improved understanding of the role of the immune system in cancer has led to the identification of novel therapeutic targets, which are being investigated for their potential to provide durable responses. In this review, we will summarize the role of the immune system in HNSCC, the rationale behind immunotherapy strategies and their clinical applications.

Entities:  

Keywords:  Checkpoint inhibitors; head and neck cancer; immune system; immunotherapy

Year:  2016        PMID: 27275486      PMCID: PMC4876265          DOI: 10.21037/atm.2016.03.34

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  78 in total

Review 1.  Head and neck cancer stem cells.

Authors:  S Krishnamurthy; J E Nör
Journal:  J Dent Res       Date:  2011-09-20       Impact factor: 6.116

2.  Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.

Authors:  Caroline J Voskens; Duane Sewell; Ronna Hertzano; Jennifer DeSanto; Sandra Rollins; Myounghee Lee; Rodney Taylor; Jeffrey Wolf; Mohan Suntharalingam; Brian Gastman; John C Papadimitriou; Changwan Lu; Ming Tan; Robert Morales; Kevin Cullen; Esteban Celis; Dean Mann; Scott E Strome
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

3.  Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance.

Authors:  Nobuyuki Fujii; Kohei Shomori; Tatsushi Shiomi; Motoki Nakabayashi; Chikako Takeda; Kazuo Ryoke; Hisao Ito
Journal:  J Oral Pathol Med       Date:  2012-02-02       Impact factor: 4.253

Review 4.  Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations.

Authors:  Kerry S Campbell; Amanda K Purdy
Journal:  Immunology       Date:  2011-01-07       Impact factor: 7.397

5.  Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.

Authors:  W C To; B G Wood; J C Krauss; M Strome; R M Esclamado; P Lavertu; D Dasko; J A Kim; G E Plautz; B E Leff; V Smith; K Sandstrom-Wakeling; S Shu
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2000-10

6.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

7.  Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors.

Authors:  Duane A Sewell; Zhen Kun Pan; Yvonne Paterson
Journal:  Vaccine       Date:  2008-08-03       Impact factor: 3.641

8.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

Authors:  Cécile Badoual; Stéphane Hans; Nathalie Merillon; Cordélia Van Ryswick; Patrice Ravel; Nadine Benhamouda; Emeline Levionnois; Mevyn Nizard; Ali Si-Mohamed; Nicolas Besnier; Alain Gey; Rinat Rotem-Yehudar; Hélène Pere; Thi Tran; Coralie L Guerin; Anne Chauvat; Estelle Dransart; Cécile Alanio; Sebastien Albert; Beatrix Barry; Federico Sandoval; Françoise Quintin-Colonna; Patrick Bruneval; Wolf H Fridman; Francois M Lemoine; Stephane Oudard; Ludger Johannes; Daniel Olive; Daniel Brasnu; Eric Tartour
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

9.  High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas.

Authors:  E Lukesova; J Boucek; E Rotnaglova; M Salakova; E Koslabova; M Grega; T Eckschlager; B Rihova; B Prochazka; J Klozar; R Tachezy
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

10.  Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model.

Authors:  Keita Inoue; Noriko Saegusa; Maho Omiya; Tadashi Ashizawa; Haruo Miyata; Masaru Komiyama; Akira Iizuka; Akiko Kume; Takashi Sugino; Ken Yamaguchi; Yoshio Kiyohara; Masahiro Nakagawa; Yasuto Akiyama
Journal:  Cancer Sci       Date:  2015-02-04       Impact factor: 6.716

View more
  32 in total

1.  Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.

Authors:  Amber M Bates; Emily A Lanzel; Fang Qian; Taher Abbasi; Shireen Vali; Kim A Brogden
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2017-05-25

2.  Overview of advances in cancer immunotherapy.

Authors:  Vassiliki Kotoula; George Fountzilas
Journal:  Ann Transl Med       Date:  2016-07

Review 3.  Modulators of Redox Metabolism in Head and Neck Cancer.

Authors:  Xiaofei Chen; Jade Mims; Xiumei Huang; Naveen Singh; Edward Motea; Sarah M Planchon; Muhammad Beg; Allen W Tsang; Mercedes Porosnicu; Melissa L Kemp; David A Boothman; Cristina M Furdui
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

Review 4.  T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma.

Authors:  Daniele Maggioni; Lorenzo Pignataro; Werner Garavello
Journal:  Oncoimmunology       Date:  2017-05-04       Impact factor: 8.110

Review 5.  Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells.

Authors:  Shannon M Clayton; Joehleen A Archard; Joseph Wagner; D Gregory Farwell; Arnaud F Bewley; Angela Beliveau; Andrew Birkeland; Shyam Rao; Marianne Abouyared; Peter C Belafsky; Johnathon D Anderson
Journal:  Stem Cells Dev       Date:  2020-01-30       Impact factor: 3.272

6.  Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma.

Authors:  Abeer A Alsofyani; Rawiah A Alsiary; Alaa Samkari; Baraa T Alhaj-Hussain; Jalaluddin Azam Khan; Jaudah Al-Maghrabi; Aisha Elaimi; Mohammed H Al-Qahtani; Adel M Abuzenadah; Ashraf Dallol
Journal:  J Appl Genet       Date:  2017-08-16       Impact factor: 3.240

7.  Bitter Melon Prevents the Development of 4-NQO-Induced Oral Squamous Cell Carcinoma in an Immunocompetent Mouse Model by Modulating Immune Signaling.

Authors:  Subhayan Sur; Robert Steele; Rajeev Aurora; Mark Varvares; Katherine E Schwetye; Ratna B Ray
Journal:  Cancer Prev Res (Phila)       Date:  2017-10-23

8.  A PIK3CA transgenic mouse model with chemical carcinogen exposure mimics human oral tongue tumorigenesis.

Authors:  Melody T Tan; Jean G Wu; Juan Luis Callejas-Valera; Richard A Schwarz; Ann M Gillenwater; Rebecca R Richards-Kortum; Nadarajah Vigneswaran
Journal:  Int J Exp Pathol       Date:  2020-05-21       Impact factor: 1.925

9.  T-Lymphocyte Activation Is Correlated With the Presence of Anti-EBV in Patients With Laryngeal Squamous Cell Carcinoma.

Authors:  Janusz Klatka; Anna Hymos; Anna Szkatuła-Łupina; Ewelina Grywalska; Barbara Klatka; Michał Terpiłowski; Andrzej Stepulak
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

10.  Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress.

Authors:  Wuchang Zhang; Wei Liu; Lingfei Jia; Demeng Chen; Insoon Chang; Michael Lake; Laurent A Bentolila; Cun-Yu Wang
Journal:  Mol Cell       Date:  2021-03-19       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.